COVID-19: Medication Management of Mild Illness in the Outpatient Setting Clinical Guideline

Version 5.1 approved 29 April 2024

Since the emergence of COVID-19 there have been significant developments in the antiviral and immunomodulatory medications recommended for patients with COVID-19.

The COVID-19: Medication Management of Mild Illness in the Outpatient Setting (PDF 823KB) only addresses the use of disease-modifying treatments for COVID-19 in adult patients with mild illness who DO NOT require supplemental oxygen or hospitalisation for COVID-19. It is intended to guide treatment of patients in the outpatient setting including in the COVID-19 Care Centre.

This guideline does not:

  • provide guidance of the overall care for patients with COVID-19
  • provide advice regarding supportive therapies recommended for COVID-19
  • provide advice regarding disease-modifying therapies recommended for patients hospitalised with COVID-19
  • provide information regarding the prevention of COVID-19 nor does it provide information regarding post exposure prophylaxis for COVID-19

For information related to the management and care of patients with COVID-19 please refer to:

  • COVID-19 Disease-modifying treatment recommendations for hospitalised adult patients (CALHN-GDE05778) - available on eCentral
  • COVID–19 (SARS–COV–2) – Management Guide (CALHN–PRC05409) - available on eCentral
  • CALHN COVID–19 internet page

Medication recommendations for COVID-19 can change rapidly due to medication shortages, ongoing research and as novel agents are discovered. For the most up to date Australian guidelines and recommendations refer to: